![](/img/cover-not-exists.png)
14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
F. Suzuki, K. Ikeda, J. Toyota, Y. Karino, T. Ohmura, K. Chayama, S. Takahashi, Y. Kawakami, H. Ishikawa, H. Watanabe, W. Hu, F. McPhee, E. Hughes, H. KumadaVolume:
56
Year:
2012
Language:
english
DOI:
10.1016/s0168-8278(12)60028-2
File:
PDF, 117 KB
english, 2012